Dr. Shahid is a cardiovascular/metabolic pharmacologist/physiologist. He earned his PhD, in cardiovascular pharmacology from the University of Delhi. He completed his postdoctoral fellowship in cardiovascular and metabolic medicine in 2012 at Massachusetts General Hospital (MGH), Harvard Medical School in Boston. He went on to become an Instructor in Pharmacology at Harvard Medical School till 2017. Prior to coming to ÎÞÂëȺ½», Dr. Shahid was an Associate Professor and the Director of Research at Chicago State University College of Pharmacy. Dr. Shahid has an active research program primarily focused on the role of immune cells in metabolic and cardiovascular disorders. Dr. Shahid’s research has been supported by funding from the National Institute of Health (NIH), the American Heart Association, Harvard University, and Chicago State University. He was awarded the Faculty Excellence Award in Research for three consecutive years which is given to the best researcher at the Chicago State University. He has been invited as a guest speaker at many reputed institutions including MGH, Rush University, California Northstate University, and internationally at Leducq Foundation, University of Cambridge; Northern Border University, KSA; and Hamdard University, New Delhi.

Courses

• Fundamentals of Pharmacology (YPHS 514)
• Pharmacology II (YPHS 626)
• Pharmacology III (YPHS 627)
• Research Elective (YELS 901)

Research Interest

Dr. Shahid’s primary research interest consist of understanding the role of immune cells, particularly macrophages in the pathogenesis of cardiovascular and metabolic disorders and exploring its translational significance. The ongoing research in his laboratory is particularly investigating the role of various immune cells-specific Immediate Early Response Gene X-1 (IEX-1) in the development of obesity, atherosclerosis, and osteoporosis. His lab employs several unique mouse models such as tissue-specific conditional knockout, double mutant, and transgenic mice, as well as various state-of-the-art techniques including in situ imaging system, fluorescent microscope, siRNA-mediated gene silencing etc.

In addition to the above-mentioned projects, Dr. Shahid is also interested in understanding the pathophysiology of cardiac hypertrophy. His lab previously reported that bone morphogenetic protein (BMP) signaling contributes to the development of cardiac hypertrophy and its blockade prevented pressure-induced cardiac hypertrophy and fibrosis in mice. The current investigation is focused on determining the underlying molecular mechanism by which BMP signaling promotes hypertrophy and its translational significance.

Funding

• National Institute of Health SC3
• American Heart Association AIREA
• National Institute of Health KO1
• Harvard University Shore’s Fellowship

Recent Publication

1. Siddiqui MR, Reddy NM, Faridi HM, Shahid M, Shanley TP. Metformin alleviates lung-endothelial hyperpermeability by regulating cofilin-1/PP2AC pathway. Front Pharmacol. 2023;14:1211460.
2. Hughes JA, Martin T, Gladwell TD, Akiyode O, Purnell MC, Shahid M, Moultry AM, Rapp KI, Unonu J. Lessons from a cross-institutional online professional development pilot. Curr Pharm Teach Learn. 2023 May;15(5):534-540. 
3. Basist P; Parveen B, Zahiruddin S, Gaurav A, Parveen R, Khan MA, Krishnan A, Shahid M, Ahmad S. Potential Nephroprotective Phytochemicals: Mechanism and Future Prospects. J Ethnopharmacol. 2021:283:114743
4. Hermes E, Wu MX, Shahid M*. Browning keeps Obesity at Bay: A Perspective on Article “IEX-1 Deficiency that Induces Browning of White Adipose Tissue and resists Diet-induced Obesity. Perspectives: Academic Journal. 2019 Feb 28; p-236. *Corresponding author
5. Shah D, Das P, Alam MA, Mahajan N, Romero F, Shahid M, Singh H, Bhandari V. MicroRNA-34a Promotes Endothelial Dysfunction and Mitochondrial-Mediated Apoptosis in Murine Models of Acute Lung Injury. Am J Respir Cell Mol Biol. 2019; 60:465-477. PMID:30512967.
6. Siddiqui MR, Akhtar S, Shahid M, Tauseef M, McDonough K, Shanley TP. miR-144 Mediated Inhibition of ROCK1 Protects Against LPS Induced Lung Endothelial Hyperpermeability. Am J Respir Cell Mol Biol. 2019;61:257-265. PMID: 30811958.
7. Shahid M*, Hermes EL, Chandra D, Tauseef M, Siddiqui MR, Faridi MH, Wu MX, Emerging potential of immediate early response gene x-1 in cardiovascular and metabolic diseases. JAHA 2018 Nov 6; 7(21): e009261.
8. Shahid M*, Javed AA, Chandra D, Ramsey HE, Shah D, Khan MF, Zhao L, Wu MX. IEX-1 deficiency induces browning of white adipose tissue and resists diet-induced obesity. Sci Rep. 2016;6:24135.
9. Shahid M*, Spagnolli E, Thoonen R, Ernande L, Kolodziej SA, , Leyton PA, Cheng J, Tainsh RET, Mayeur C, Rhee DK, Wu MX, Scherrer-Crosbie M, Buys ES, Zapol WM, Bloch KD, Bloch DB. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2016;310:H984-94. *Corresponding author
10. Lei C, Yu B, Shahid M, Beloiartsev A, Bloch KD, Zapol WM. Inhaled Nitric Oxide attenuates the adverse effects of transfusing stored syngeneic red blood cells in mice with endothelial dysfunction after hemorrhagic shock. Anesthesiology 2012; 117:1190-202
11. Buys ES, Raher MJ, Kirby A, Shahid M, Baron DM, Hayton SR, Tainsh LT, Sips PY, Rauwerdink K, Yan Q, Tainsh RET, Shakartzi HR, Stevens C, Decaluwe K, Rodrigues-Machado MG, Malhotra R, de Voorde JV, Wang T, Vrouckaert P, Daly MJ, Bloch KD. Genetic modifier of hypertension in soluble guanylate cyclase alpha1-deficient mice. J Clin Invest 2012; 122:2316-2.